Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Amicus Therapeutics stock

Own Amicus Therapeutics stock in just a few minutes.

Amicus Therapeutics, Inc is a biotechnology business based in the US. Amicus Therapeutics shares (FOLD) are listed on the NASDAQ and all prices are listed in US Dollars. Amicus Therapeutics employs 483 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Amicus Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – FOLD – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Amicus Therapeutics share price

Use our graph to track the performance of FOLD stocks over time.

Amicus Therapeutics shares at a glance

Information last updated 2021-04-30.
52-week range$8.83 - $25.39
50-day moving average $9.93
200-day moving average $17.07
Wall St. target price$18.14
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.13

Buy Amicus Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Amicus Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Amicus Therapeutics financials

Revenue TTM $260.9 million
Gross profit TTM $229.8 million
Return on assets TTM -17.55%
Return on equity TTM -72.59%
Profit margin -106.12%
Book value $1.09
Market capitalisation $2.7 billion

TTM: trailing 12 months

Shorting Amicus Therapeutics shares

There are currently 32.0 million Amicus Therapeutics shares held short by investors – that's known as Amicus Therapeutics's "short interest". This figure is 3.3% down from 33.1 million last month.

There are a few different ways that this level of interest in shorting Amicus Therapeutics shares can be evaluated.

Amicus Therapeutics's "short interest ratio" (SIR)

Amicus Therapeutics's "short interest ratio" (SIR) is the quantity of Amicus Therapeutics shares currently shorted divided by the average quantity of Amicus Therapeutics shares traded daily (recently around 3.2 million). Amicus Therapeutics's SIR currently stands at 9.92. In other words for every 100,000 Amicus Therapeutics shares traded daily on the market, roughly 9920 shares are currently held short.

However Amicus Therapeutics's short interest can also be evaluated against the total number of Amicus Therapeutics shares, or, against the total number of tradable Amicus Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Amicus Therapeutics's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 Amicus Therapeutics shares in existence, roughly 120 shares are currently held short) or 0.122% of the tradable shares (for every 100,000 tradable Amicus Therapeutics shares, roughly 122 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Amicus Therapeutics.

Find out more about how you can short Amicus Therapeutics stock.

Amicus Therapeutics share dividends

We're not expecting Amicus Therapeutics to pay a dividend over the next 12 months.

Amicus Therapeutics share price volatility

Over the last 12 months, Amicus Therapeutics's shares have ranged in value from as little as $8.83 up to $25.39. A popular way to gauge a stock's volatility is its "beta".

FOLD.US volatility(beta: 1.17)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Amicus Therapeutics's is 1.1748. This would suggest that Amicus Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Amicus Therapeutics overview

Amicus Therapeutics, Inc. , a biotechnology company, focuses on discovering, developing, and delivering medicines for people living with rare metabolic diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data; gene therapies for Fabry and Pompe diseases, as well as for various types of Batten diseases; enzyme replacement therapies for Pompe diseases; and CDKL5 deficiency disorder product candidates. The company also has additional gene therapies in active preclinical development, including gene therapies for mucopolysaccharidosis type IIIB, as well as a next generation program in mucopolysaccharidosis type IIIA. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site